NCT02876510已完成1 期
Phase I Adoptive Cellular Therapy Trial With Endogenous CD8+ T Cells (ACTolog® IMA101) Alone or in Combination With Atezolizumab in Patients With Relapsed and/or Refractory Solid Cancers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Incidence of adverse events (Safety and tolerability) of IMA101 alone or in combination with atezolizumab
研究概览
简要总结
The study purpose is to learn about the safety and tolerability of IMA101 alone (Cohort 1) or in combination with atezolizumab (Cohort 2) in patients with advanced solid cancers that express pre-defined Immatics tumor targets.
详细描述
SCREENING: Patient eligibility will be determined by HLA (human leukocyte antigen) and the main biomarkers screening. If the patient is eligible, white blood cells will be collected with a leukapheresis for the manufacture of the IMA101 product.
MANUFACTURE: IMA101 product will be made from the patient's white blood cells.
TREATMENT: IMA101 product will be administered to the patient intravenously after lymphodepleting pre-conditioning with chemotherapy (fludarabine and cyclophosphamide).
Low-dose IL-2 will be self-administered twice daily for a total of 28 doses after infusion of IMA101 product. In Cohort 2, atezolizumab will be administered every 3 weeks, starting no earlier than 3 weeks after the IMA101 product infusion and after hematologic recovery.
Patients will be monitored closely throughout the study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have pathologically confirmed advanced/metastatic cancer prior to enrollment.
- •HLA phenotype positive.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Life expectancy > 6 months prior to enrollment.
- •Patient is a candidate for a maximum of one further line of established therapy (prior to treatment with ACTolog).
- •The patient has adequate organ and marrow function per protocol
- •At least one lesion (metastasis or primary tumor) being considered accessible by non-high-risk collection procedures for biopsy.
- •The patient has adequate hepatic function per protocol
- •The patient has serum creatinine clearance ≥50 mL/min by the Cockcroft-Gault formula.
- •The patient has adequate pulmonary function per protocol
- •Acceptable coagulation status
- •Women of childbearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation.
- •Male subjects must agree to use effective contraception or abstinence while on study and for 90 days after infusion of the ACTolog T-cell product.
- •Ability of subject to understand and the willingness to sign written informed consent for study participation.
- •Confirmed availability of production capacities for the patient's ACTolog products.
- •ACTolog target expression as evaluated by the in vitro diagnostic device IMA_Detect: Patient's tumor must express at least one ACTolog target as assessed by quantitative PCR (qPCR) (to be assessed from a tumor biopsy to be performed if all other eligibility criteria are met).
- •Exclusion Criteria
- •Any condition contraindicating leukapheresis.
- •Patients with brain metastases. Patients with a history of brain metastases may be eligible, if an imaging scan with contrast enhancement not older than 4 weeks is able to exclude the existence of currently active brain metastasis.
- •HIV infection, active Hepatitis B or C infection, or active infections requiring oral or intravenous antibiotics or that can cause a severe disease and pose a severe danger to lab personnel working on patients' blood or tissue. If positive test results are not indicative of an active infection, patients can be included.
- •Treatment with excluded therapy per protocol
- •Previous extensive radiotherapy to the lung or liver during the last 4 months prior to lymphodepletion regimen.
- •The patient has cardiac conditions defined per protocol
- •Patients with prior stem cell transplantation or solid organ transplantation.
- •The patient has concurrent severe and/or uncontrolled medical disease that could compromise participation in the study
- •Active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction, abdominal carcinomatosis or other known risk factors for bowel perforation.
- •History of other malignancies (except for adequately treated basal or squamous cell carcinoma or carcinoma in situ) within the last 3 years.
- •The patient is pregnant or is breastfeeding.
- •Serious autoimmune disease per protocol
- •History of hypersensitivity to cyclophosphamide, fludarabine or IL-
- •Immunosuppression, not related to prior treatment for malignancy.
- •History of or current immunodeficiency disease or prior treatment compromising immune function at the discretion of the treating physician.
- •Patients with Grade 3 or higher immune-related toxicities related to prior checkpoint inhibitors
排除标准
- 未提供
研究组 & 干预措施
IMA101 product only (Cohort 1)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
干预措施: Fludarabine (Drug)
IMA101 product only (Cohort 1)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
干预措施: Cyclophosphamide (Drug)
IMA101 product only (Cohort 1)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
干预措施: IMA101 product (Biological)
IMA101 product only (Cohort 1)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
干预措施: Recombinant human interleukin-2 (Biological)
IMA101 product only (Cohort 1)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
干预措施: IMADetect (Diagnostic Test)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: Fludarabine (Drug)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: Cyclophosphamide (Drug)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: IMA101 product (Biological)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: Recombinant human interleukin-2 (Biological)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: IMADetect (Diagnostic Test)
IMA101 product + atezolizumab (Cohort 2)
Experimental
- Pre-conditioning by non-myeloablative chemotherapy with Fludarabine and Cyclophosphamide
- Infusion of the IMA101 T-cell product(s)
- Post-infusion administration of low-dose recombinant human interleukin-2
- Treatment with atezolizumab every 3 weeks after IMA101 product infusion, for 1 year
干预措施: Atezolizumab (Drug)
结局指标
主要结局
Incidence of adverse events (Safety and tolerability) of IMA101 alone or in combination with atezolizumab
时间窗: up to 18 months
次要结局
- Peripheral T-cell persistence (assessment of frequency of T-cells over time)(up to 18 months)
- Tumor response per Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 and immune-related RECIST (irRECIST)(up to 18 months)
研究者
研究点 (1)
Loading locations...
相似试验
终止
1 期
Exploratory Study of IMM01 for Injection in the Treatment of Refractory or Recurrent Hematologic MalignancyHematologic MalignancyNCT05860075ImmuneOnco Biopharmaceuticals (Shanghai) Inc.73
已完成
1 期
Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected AdultsHIV InfectionsNCT03409276National Institute of Allergy and Infectious Diseases (NIAID)60
已完成
1 期
Safety and Tolerability of CV8102 Alone and in Combination With a Rabies Virus Vaccine in Healthy AdultsRabiesNCT02238756CureVac72
已完成
1 期
IBI322 Monotherapy or Combination Therapy in Subjects With Advanced Malignant Tumors.Advanced Solid TumorNCT04912466Innovent Biologics (Suzhou) Co. Ltd.61
已完成
1 期
TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)Solid TumorRecurrent Solid TumorsRefractory Solid TumorsCancerNCT03247309Immatics US, Inc.7